GSK's critics reject company's much-touted turnaround

The New York Times examines GlaxoSmithKline's insistence that it is on the road to recovery as it rebounds from a series of setbacks and declining profits from some key blockbusters. Company executives insist that GSK has 15 top drugs in late-stage development, part of 147 trials underway. But several market analysts say that GSK is being beaten to the drug market by its competitors, has several drugs that aren't living up to expectations and has never successfully reorganized its research division since the big merger between Glaxo Wellcome and SmithKline Beecham five years ago.

- read this story from The New York Times for more

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.